A new study used mouse models to test whether stronger circadian rhythms help the brain recover after stroke. The research reported that interventions targeting daily rhythms improved outcomes long after the initial injury.
The work focused on the glymphatic system, which moves cerebrospinal fluid through the brain to clear waste. Scientists first described the glymphatic system in 2012 and later found its activity follows daily rhythms independent of sleep.
Researchers tested timed light exposure, melatonin, a drug called KL001, and time-restricted feeding. KL001 and time-restricted feeding were given to mice three days after stroke. Treated animals showed better motor recovery, smaller lesions, and lower inflammatory signals. The findings are from animal models and need more research before human trials.
Difficult words
- circadian rhythm — Natural 24-hour cycle in body activity.circadian rhythms
- glymphatic system — Brain pathway that moves fluid and waste.
- cerebrospinal fluid — Clear fluid that surrounds brain and spinal cord.
- melatonin — Hormone that helps control sleep timing.
- lesion — Area of tissue damaged by injury or disease.lesions
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Have you ever changed your daily routine to try to feel better? What did you change?
- Which of the study interventions would be easiest for a person to try and why?
Related articles
Engineered antibodies could block cytomegalovirus
A research team created changed antibodies that stop human cytomegalovirus from disabling immune responses. Lab tests show the antibodies reduce virus spread, but researchers say more testing is needed before they can be used in people.
Brown study suggests targeting mTORC2 could help fight cancer
Researchers at Brown University report that blocking the mTORC2 protein complex, while leaving mTORC1 active, may stop cancer growth signals without triggering survival pathways. The work offers a new direction for designing cancer drugs.
